



E-ISSN: 3078-9117
P-ISSN: 3078-9109
Impact Factor (RJIF): 5.92
www.hygienejournal.com
JHCHN 2025; 2(2): 52-55
Received: 02-09-2025
Accepted: 05-10-2025

C Mary Sophia
RN, RM, M.Sc. (N) - OBG,
Ph.D., Nursing Tutor Grade
II, SHIR-LK Karigiri School
of Nursing, Tamil Nadu, India

V Archana
M.Sc. (N), Associate Professor,
Department of Community
Health Nursing, Arcot Sri
Mahalakshmi Women's College
and School of Nursing, Tamil
Nadu, India

Corresponding Author:
V Archana
M.Sc. (N), Associate Professor,
Department of Community
Health Nursing, Arcot Sri
Mahalakshmi Women's College
and School of Nursing, Tamil
Nadu, India

Struma ovarii

C Mary Sophia and V Archana

DOI: <https://www.doi.org/10.33545/30789109.2025.v2.i2.A.26>

Abstract

Struma ovarii is a rare and specialized variant of ovarian teratoma composed predominantly of mature thyroid tissue. It represents approximately 1–5% of ovarian teratomas and less than 1% of all ovarian tumors. Although most cases are benign and asymptomatic, a small proportion may produce thyroid hormones leading to hyperthyroidism or undergo malignant transformation into papillary or follicular thyroid carcinoma. Struma ovarii usually occurs in women of reproductive age and is commonly unilateral. Clinical presentation varies from an incidental pelvic mass to pelvic pain, abdominal distension, menstrual irregularities, or thyrotoxic symptoms in functioning tumors. Diagnosis relies on imaging studies and laboratory findings, with confirmation by histopathology. Management primarily involves surgical excision, while malignant or metastatic cases may require thyroidectomy and radioactive iodine therapy. The prognosis is generally favorable, but long-term follow-up is recommended due to the risk of recurrence and rare complications.

Keywords: Struma ovarii, ovarian teratoma, thyroid tissue, hyperthyroidism, malignant transformation, ovarian tumor, thyrotoxicosis, surgical management

Introduction

Struma ovarii is a rare, specialized form of ovarian teratoma composed predominantly of mature thyroid tissue. It accounts for approximately 1–5% of all ovarian teratomas and <1% of all ovarian tumors. Although typically benign, struma ovarii can occasionally undergo malignant transformation, most commonly to papillary or follicular thyroid carcinoma. Recognition of this entity is clinically significant due to its unique endocrine and radiologic feature.

Definition

Struma ovarii is a rare type of ovarian teratoma in which thyroid tissue constitutes more than 50% of the tumor and produce thyroid hormones, sometimes leading to hyperthyroidism.

EPIDEMIOLOGY

- Occurs mainly in reproductive age women (30–60 yrs)
- Rare incidenc
- Majority of cases unilateral
- Bilateral involvement <5%
- Hyperthyroidism develops in only ~5–10% of patients

Types of Struma Ovarii

1. Benign Struma Ovarii

- Composed of mature thyroid tissue
- Most common type (~95%)
- Often asymptomatic May occasionally cause hyperthyroidism

2. Malignant Struma Ovarii

- Papillary thyroid carcinoma (most common)
- Follicular thyroid carcinoma
- Poorly differentiated or anaplastic carcinoma (rare)
- **Potential for metastasis:** Peritoneum, liver, bones, lungs

3. Functional (Hyperthyroid-producing) Struma Ovarii

- This form actively secretes thyroid hormones
- Leads to hyperthyroidism / thyrotoxicosis
- TSH suppressed, ovarian mass shows radioactive iodine uptake

4. Struma Ovarii within Ovarian Teratoma


- Mixed mature teratomatous tissues present
- Thyroid tissue $\geq 50\%$ of the specimen \rightarrow termed struma ovarii
- Can be benign or rarely malignant

Pathogenesis

Struma ovarii originates from totipotent germ cells within a mature cystic teratoma. These cells differentiate into thyroid follicular epithelium, forming colloid-filled follicles resembling normal thyroid tissue.

Malignant progression involves

Genetic instability of teratomatous thyroid cells
Activation of RAS/BRAF pathways in rare malignant variants



Metastasis pattern mimics thyroid carcinomas

Fig 1: Struma ovarii






Fig 2: Benign struma ovarii

Pathophysiology



**Signs and symptoms**

- Gynecologic Symptom
- Pelvic pain
- Abdominal distension
- Palpable pelvic mass
- Menstrual irregularities

Thyrotoxic Symptoms (if functioning) Tachycardia

- Heat intolerance
- Weight loss
- Anxiety & tremors
- Elevated T4, suppressed TSH

Diagnostic work-up

- Physical Examination
- Pelvic mass on bimanual exam
- Goiter typically absent, unlike systemic hyperthyroidism

Laboratory Findings

Thyroid function tests abnormal only if hormonally active

Serum thyroglobulin may be elevated

Imaging

- **Ultrasound:** complex, cystic-solid ovarian mass
- **MRI:** areas of low signal intensity due to viscous colloid
- **CT:** variable attenuation depending on colloid density

Management

- Benign Struma Ovarii
- Surgical resection
- Cystectomy or unilateral oophorectomy

Malignant Struma Ovarii

1. Surgical staging similar to ovarian carcinoma
2. Total thyroidectomy sometimes recommended
3. Radioactive iodine therapy if metastasis or extra-ovarian spread

Thyroid suppression with levothyroxine.**Prognosis**

- Benign cases: Excellent outcome
- Malignant transformation: Rare, but can metastasize
- Long-term survival generally favorable with appropriate management
- Recurrence rate low, but follow-up monitoring recommended.

Complications

- Ovarian torsion
- Rupture
- Malignant transformation
- Thyrotoxicosis and thyroid storm (rare)

Follow-up

- After surgery:
- Monitor pelvic recurrence by imaging
- Thyroid function tests periodically in functioning variants
- Thyroglobulin monitoring in malignant cases.

Nursing Diagnosis

1. Hyperthermia related to increased metabolic rate secondary to thyroid-hormone-secreting ovarian tumor.
2. Decreased Cardiac Output related to tachycardia and increased cardiac workload.
3. Acute Pain related to abdominal mass effect or post-operative surgical incision.
4. Anxiety related to uncertainty of diagnosis, treatment outcomes, and potential malignancy.
5. Deficient Knowledge related to unfamiliarity with condition, treatment, and long-term follow-up needs.

Conclusion

Struma ovarii is an uncommon ovarian tumor distinguished by its thyroid tissue composition. While typically benign, its unique endocrine capability and potential malignant transformation require careful diagnosis and multidisciplinary management. Awareness of its clinical presentation and imaging-histopathologic correlation is essential for optimal treatment and prognosis.

References

1. Acelli A, Ciucci A, Iualé A, Stigliano V. Struma ovarii: clinical presentation, diagnosis and management: a review. *Gynecol Endocrinol.* 2023;39(4):241–248.
2. Janszen EWM, van Dijke CF, Willemse PHB, de Vries EGE. Struma ovarii: diagnosis and therapy. *Gynecol Oncol.* 1995;59(3):377–380.
3. Makani S, Kim W, Gaba AR. Struma ovarii—clinical and pathologic features: a review. *Ann Diagn Pathol.* 2004;8(1):52–56.
4. Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC. Malignant struma ovarii: an analysis of 88 cases. *Int J Gynecol Pathol.* 2009;28(5):405–422.
5. Yassa L, Sadow P, Marqusee E. Malignant struma ovarii. *Nat Clin Pract Endocrinol Metab.* 2008;4(8):469–472.

How to Cite This Article

Sophia CM, Archana V. Struma ovarii. *Journal of Hygiene and Community Health Nursing.* 2025;2(2):52-55

Creative Commons (CC) License

This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.